Literature DB >> 30243879

Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer.

Christopher C M Neumann1, Ellen von Hörschelmann1, Anja Reutzel-Selke1, Elisabeth Seidel1, Igor Maximilian Sauer1, Johann Pratschke1, Marcus Bahra1, Rosa Bianca Schmuck2.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant solid tumor with a dismal prognosis. The stroma component makes up to 90% of the tumor mass and is thought to be one of the main reasons for the tumor's high chemoresistance. Cancer associated fibroblasts (CAFs) have previously been identified to be the key stromal players. This is the first time we provide detailed in vitro experiments investigating tumor-stromal interactions when exposed to three well-known chemotherapeutic agents.
METHODS: Monocultures, indirect and direct co-cultures of two PDAC cell lines (AsPC and Panc-1) and six primary patients derived CAFs were treated with gemcitabine, nab-paclitaxel and the γ-secretase-inhibitor (GSI) DAPT. The cell viability of each component was measured with XTT. Finally, IL-6 concentrations of the supernatants were analyzed.
RESULTS: On the contrary to PDAC cell lines, CAF monocultures hardly responded to any treatment which suggested that stroma (CAFs) itself is more resistant to standard chemo-treatments than the epithelial cancer cells. Moreover, only a weak chemotherapeutic response was observed in direct co-cultures of cancer cells with CAFs. A change in the morphology of direct co-cultures was accompanied with the chemoresistance. CAFs were observed to build cage-like structures around agglomerates of tumor cells. High levels of IL-6 were also associated with a reduced response to therapy. Indirect co-cultures make the tumor-stromal interaction more complex.
CONCLUSIONS: CAFs are highly chemoresistant. Direct cell-cell contact and high levels of IL-6 correlate with a high chemoresistance.
Copyright © 2018 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atroma targeted therapy; Cancer associated fibroblasts; Cancer–stroma co-culture; Pancreatic cancer; Tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 30243879     DOI: 10.1016/j.hbpd.2018.09.004

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  10 in total

1.  A new era: tumor microenvironment in chemoresistance of pancreatic cancer.

Authors:  Xueping Zhao; Zongze Li; Zongting Gu
Journal:  J Cancer Sci Clin Ther       Date:  2022-02-15

2.  MiR-887-3p Negatively Regulates STARD13 and Promotes Pancreatic Cancer Progression.

Authors:  Xiaobo Xu; Shusen Zheng
Journal:  Cancer Manag Res       Date:  2020-07-22       Impact factor: 3.989

Review 3.  Update on current pancreatic treatments: from molecular pathways to treatment.

Authors:  Konstantinos Sapalidis; Christoforos Kosmidis; Varvara Funtanidou; Athanasios Katsaounis; Amastasios Barmpas; Georgios Koimtzis; Stylianos Mantalobas; Vyron Alexandrou; Zoi Aidoni; Charilaos Koulouris; Efstathios Pavlidis; Dimitrios Giannakidis; Valeriu Surlin; Stelian Pantea; Victor Strambu; Rogoveanu Otilia Constantina; Aikaterini Amaniti; Paul Zarogoulidis; Stelian Mogoantă; Isaak Kesisoglou; Chrysanthi Sardeli
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

Review 4.  Ping-Pong-Tumor and Host in Pancreatic Cancer Progression.

Authors:  Wei Mu; Zhe Wang; Margot Zöller
Journal:  Front Oncol       Date:  2019-12-16       Impact factor: 6.244

Review 5.  Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer.

Authors:  Manoj Amrutkar; Ivar P Gladhaug
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

6.  TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma.

Authors:  Kasia Trebska-McGowan; Mehdi Chaib; Marcus A Alvarez; Rita Kansal; Ajeeth K Pingili; David Shibata; Liza Makowski; Evan S Glazer
Journal:  J Gastrointest Surg       Date:  2021-07-14       Impact factor: 3.452

Review 7.  Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer.

Authors:  Xinglong Geng; Hongze Chen; Liang Zhao; Jisheng Hu; Wenbo Yang; Guanqun Li; Chundong Cheng; Zhongjie Zhao; Tao Zhang; Le Li; Bei Sun
Journal:  Front Cell Dev Biol       Date:  2021-07-15

Review 8.  Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment.

Authors:  Jeffrey Norton; Deshka Foster; Malini Chinta; Ashley Titan; Michael Longaker
Journal:  Cancers (Basel)       Date:  2020-05-25       Impact factor: 6.639

9.  Establishment and Characterization of Paired Primary Cultures of Human Pancreatic Cancer Cells and Stellate Cells Derived from the Same Tumor.

Authors:  Manoj Amrutkar; Emma Kristine Larsen; Monica Aasrum; Anette Vefferstad Finstadsveen; Per Arne Andresen; Caroline S Verbeke; Ivar P Gladhaug
Journal:  Cells       Date:  2020-01-16       Impact factor: 6.600

10.  Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor.

Authors:  Iván A González; Liang-I Kang; Gregory A Williams; Jingxia Liu; David G DeNardo; William G Hawkins; Deyali Chatterjee
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.